BioCentury | Aug 6, 2015
Distillery Therapeutics

Therapeutics: Fascin 1 actin-bundling protein (FSCN1)

...Cancer INDICATION: Cancer In vitro and mouse studies suggest inhibiting FSCN1 activity could help prevent or...
...cancers. In an in vitro actin-bundling assay, high throughput screening identified a compound that inhibited FSCN1-mediated...
...Next steps could include testing the FSCN1 inhibitor in additional models of metastatic cancer. TARGET/MARKER/PATHWAY: Fascin 1 actin-bundling protein (FSCN1)...
BioCentury | Jul 28, 2011
Distillery Therapeutics

Indication: Cancer

...contact information Cancer Melanoma Acid phosphatase 5 tartrate resistant (ACP5); fascin homolog 1 actin-bundling protein (FSCN1...
...domain containing 4 (VSIG4) A study in patient tissue, mice and cell culture suggests ACP5, FSCN1...
BioCentury | Apr 22, 2010
Distillery Therapeutics

Indication: Cancer

...that inhibiting FSCN1 could help prevent tumor metastasis. In vitro, the migrastatin analog macroketone bound FSCN1...
...inhibition of FSCN1 with macroketone or small interfering RNA reduced lung metastases compared with controls. FSCN1...
...associated with lower overall and metastasis-free survival. Ongoing work includes pharmacokinetic and toxicity studies of FSCN1...
Items per page:
1 - 3 of 3